Should You Invest in Humana (HUM)?

Core Insights - Ariel Global Fund's third-quarter 2025 performance was influenced by global equity rallies, AI enthusiasm, resilient corporate earnings, and the first U.S. rate cut of the year, with the fund returning +4.99% compared to +7.62% for the MSCI ACWI Index [1] Group 1: Fund Performance - The Ariel Global Fund traded +4.99% higher in Q3 2025, underperforming the MSCI ACWI Index which returned +7.62% and the MSCI ACWI Value Index which returned +6.13% [1] - The fund's performance was driven by factors such as AI enthusiasm and targeted policy easing across key regions [1] Group 2: Humana Inc. (NYSE:HUM) Overview - Humana Inc. offers medical and specialty insurance products, with a one-month return of -18.64% and a 52-week loss of 20.37%, closing at $234.10 per share with a market capitalization of $28.156 billion on November 18, 2025 [2] - The fund initiated a position in Humana, focusing on its Medicare Advantage, Medicaid, and specialty healthcare services [3] Group 3: Humana Inc. Performance and Outlook - Humana's largest Medicare Advantage plan, H5216, was downgraded from 4.5 to 3.5 Stars in 2025, affecting eligibility for federal bonus payments in 2026 [3] - There is optimism regarding Humana's potential to regain a higher Star rating in 2027, which could restore access to quality-based federal bonuses [3] Group 4: Hedge Fund Interest - Humana Inc. was held by 69 hedge fund portfolios at the end of Q2 2025, a decrease from 73 in the previous quarter [4] - While Humana is recognized for its investment potential, certain AI stocks are viewed as having greater upside potential and less downside risk [4]